Safety and neutralization antibody levels of inactivated SARS-CoV-2 vaccine in adult patients with Myasthenia Gravis: a prospective observational cohort study
Background and objectives Myasthenia gravis (MG) is an autoimmune disease affecting the neuromuscular junction. No cohort study has investigated the efficacy of inactivated vaccines in patients with MG. Materials and methods This prospective observational cohort study included healthy controls (HCs) and patients with MG with or without immunosuppressive treatment. Vaccination occurred between May and December 2021. Patients with MG were subjected to a clinical scale assessment for disease severity. The neutralization antibodies (Nabs) levels were measured in all participants using the pseudovirus neutralization assay. Results Twenty-one patients (Female/Male:10/11); age median [interquartile range (IQR)]: 43 [30, 56]) were included in this study. Two patients (2/21) were lost during follow-up after enrollment. No sustained vaccine-related adverse effects occurred in any visit of patients with MG. No exacerbation of MG was observed. Acetylcholine receptor antibody (AChR-Ab) levels showed no statistically significant changes between the first and second visit (median [IQR]: 2.22 [0.99, 2.63] nmol/L vs. 1.54 [1.07, 2.40] nmol/L, p = 0.424). However, levels of AChR-Ab decreased at the third visit (median [IQR]: 2.22 [0.96, 2.70] nmol/L vs. 1.69 [0.70, 1.85] nmol/L, p = 0.011). No statistically significant difference in Nabs levels was found between HCs and patients with MG (median [IQR]: 102.89 [33.13, 293.86] vs. 79.29 [37.50, 141.93], p = 0.147). Discussion The safety of the SARS-CoV-2 inactivated vaccine was reconfirmed in this study. No significant difference in Nabs level was found between patients with MG and HCs. Nabs levels correlated with AChR-Ab levels before vaccination and ΔAChR-Ab levels..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:45 |
|---|---|
| Enthalten in: |
Neurological sciences - 45(2023), 4 vom: 09. Nov., Seite 1707-1717 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zheng, Wei [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: | |
|---|---|
| Themen: |
Acetylcholine receptor antibody (AchR-Ab) |
| Anmerkungen: |
© Fondazione Società Italiana di Neurologia 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s10072-023-07186-w |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR055165532 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR055165532 | ||
| 003 | DE-627 | ||
| 005 | 20240316064716.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240316s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10072-023-07186-w |2 doi | |
| 035 | |a (DE-627)SPR055165532 | ||
| 035 | |a (SPR)s10072-023-07186-w-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.90 |2 bkl | ||
| 100 | 1 | |a Zheng, Wei |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Safety and neutralization antibody levels of inactivated SARS-CoV-2 vaccine in adult patients with Myasthenia Gravis: a prospective observational cohort study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © Fondazione Società Italiana di Neurologia 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Background and objectives Myasthenia gravis (MG) is an autoimmune disease affecting the neuromuscular junction. No cohort study has investigated the efficacy of inactivated vaccines in patients with MG. Materials and methods This prospective observational cohort study included healthy controls (HCs) and patients with MG with or without immunosuppressive treatment. Vaccination occurred between May and December 2021. Patients with MG were subjected to a clinical scale assessment for disease severity. The neutralization antibodies (Nabs) levels were measured in all participants using the pseudovirus neutralization assay. Results Twenty-one patients (Female/Male:10/11); age median [interquartile range (IQR)]: 43 [30, 56]) were included in this study. Two patients (2/21) were lost during follow-up after enrollment. No sustained vaccine-related adverse effects occurred in any visit of patients with MG. No exacerbation of MG was observed. Acetylcholine receptor antibody (AChR-Ab) levels showed no statistically significant changes between the first and second visit (median [IQR]: 2.22 [0.99, 2.63] nmol/L vs. 1.54 [1.07, 2.40] nmol/L, p = 0.424). However, levels of AChR-Ab decreased at the third visit (median [IQR]: 2.22 [0.96, 2.70] nmol/L vs. 1.69 [0.70, 1.85] nmol/L, p = 0.011). No statistically significant difference in Nabs levels was found between HCs and patients with MG (median [IQR]: 102.89 [33.13, 293.86] vs. 79.29 [37.50, 141.93], p = 0.147). Discussion The safety of the SARS-CoV-2 inactivated vaccine was reconfirmed in this study. No significant difference in Nabs level was found between patients with MG and HCs. Nabs levels correlated with AChR-Ab levels before vaccination and ΔAChR-Ab levels. | ||
| 650 | 4 | |a Inactivated vaccine |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a SARS-CoV-2 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Myasthenia Gravis |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Acetylcholine receptor antibody (AchR-Ab) |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Cohort study |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Cao, Xiaoxia |4 aut | |
| 700 | 1 | |a Luo, Jing |4 aut | |
| 700 | 1 | |a Liu, Zhuoting |4 aut | |
| 700 | 1 | |a Que, Wenjun |4 aut | |
| 700 | 1 | |a Guo, Xia |4 aut | |
| 700 | 1 | |a Fan, Rui |4 aut | |
| 700 | 1 | |a Long, Quanxin |4 aut | |
| 700 | 1 | |a Xiao, Fei |0 (orcid)0000-0002-5981-2922 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Neurological sciences |d Springer International Publishing, 2000 |g 45(2023), 4 vom: 09. Nov., Seite 1707-1717 |w (DE-627)SPR008581010 |w (DE-600)1481772-X |x 1590-3478 |7 nnns |
| 773 | 1 | 8 | |g volume:45 |g year:2023 |g number:4 |g day:09 |g month:11 |g pages:1707-1717 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s10072-023-07186-w |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.90 |q VZ |
| 951 | |a AR | ||
| 952 | |d 45 |j 2023 |e 4 |b 09 |c 11 |h 1707-1717 | ||